Core Ferroptosis-Related Biomarkers and miRNA Regulatory Networks in Alzheimer's Disease

Wenjia Liu1, Xin Rao2, Liyang Yu2

  • 1School of Electronic Information Engineering, Suzhou Polytechnic University, Suzhou 215104, China.

Genes
|February 27, 2026
PubMed

Insights

This study identifies nine ferroptosis-related differentially expressed genes (FRDEGs) as potential biomarkers for Alzheimer's disease (AD). These FRDEGs show significant differential expression in AD patients, suggesting their role in disease pathology and potential for diagnostic applications.

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Alzheimer's disease (AD) pathogenesis remains unclear.
  • Ferroptosis, an iron-dependent cell death, is implicated in AD.
  • Identifying AD biomarkers is crucial for early diagnosis and treatment.

Purpose of the Study:

  • To identify core ferroptosis-related genes (FRDEGs) associated with Alzheimer's disease.
  • To evaluate the potential of these FRDEGs as reliable AD biomarkers.
  • To explore the regulatory network of FRDEGs and microRNAs (miRNAs) in AD.

Main Methods:

  • Analysis of gene expression profiles from AD patients (GSE140831, GSE63060, GSE63061).
  • Identification of differentially expressed genes (DEGs) and ferroptosis-related DEGs (FRDEGs).
  • Validation of FRDEGs and construction of a FRDEG-miRNA interaction network.

Main Results:

  • Nine FRDEGs (ACVR1B, BRPF1, G6PD, KLHDC3, LAMP2, MTCH1, P4HB, PTPN6, RBMS1) were identified as potential AD biomarkers.
  • All nine genes showed statistically significant up-regulation in AD patients (p < 0.05).
  • A network of 11 miRNAs regulating these hub FRDEGs was constructed.

Conclusions:

  • The identified FRDEGs are significantly associated with Alzheimer's disease.
  • A core ferroptosis-related biomarker network involving miRNA regulation in AD was established.
  • Further investigation into the specific regulatory mechanisms is warranted.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K